These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37477064)

  • 1. Tacrolimus population pharmacokinetics in adult heart transplant patients.
    Paschier A; Destere A; Monchaud C; Labriffe M; Marquet P; Woillard JB
    Br J Clin Pharmacol; 2023 Dec; 89(12):3584-3595. PubMed ID: 37477064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.
    Benkali K; Rostaing L; Premaud A; Woillard JB; Saint-Marcoux F; Urien S; Kamar N; Marquet P; Rousseau A
    Clin Pharmacokinet; 2010 Oct; 49(10):683-92. PubMed ID: 20818834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
    Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
    Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
    Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
    Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?
    Brooks E; Tett SE; Isbel NM; Staatz CE
    Clin Pharmacokinet; 2016 Nov; 55(11):1295-1335. PubMed ID: 27138787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of tacrolimus in peripheral blood mononuclear cells and limited sampling strategy for estimation of exposure in renal transplant recipients.
    Wang XH; Shao K; An HM; Zhai XH; Zhou PJ; Chen B
    Eur J Clin Pharmacol; 2022 Aug; 78(8):1261-1272. PubMed ID: 35536394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients.
    Benkali K; Prémaud A; Picard N; Rérolle JP; Toupance O; Hoizey G; Turcant A; Villemain F; Le Meur Y; Marquet P; Rousseau A
    Clin Pharmacokinet; 2009; 48(12):805-16. PubMed ID: 19902988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of machine learning to predict tacrolimus exposure in liver and kidney transplant patients given the MeltDose formulation.
    Ponthier L; Marquet P; Moes DJAR; Rostaing L; van Hoek B; Monchaud C; Labriffe M; Woillard JB
    Eur J Clin Pharmacol; 2023 Feb; 79(2):311-319. PubMed ID: 36564549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf.
    Woillard JB; de Winter BC; Kamar N; Marquet P; Rostaing L; Rousseau A
    Br J Clin Pharmacol; 2011 Mar; 71(3):391-402. PubMed ID: 21284698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Pharmacokinetics and Bayesian Estimators for the Individual Dose Adjustment of a Generic Formulation of Tacrolimus in Adult Kidney Transplant Recipients.
    Marquet P; Destère A; Monchaud C; Rérolle JP; Buchler M; Mazouz H; Etienne I; Thierry A; Picard N; Woillard JB; Debord J
    Clin Pharmacokinet; 2021 May; 60(5):611-622. PubMed ID: 33230714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a population PK model of tacrolimus for adaptive dosage control in stable kidney transplant patients.
    Andreu F; Colom H; Grinyó JM; Torras J; Cruzado JM; Lloberas N
    Ther Drug Monit; 2015 Apr; 37(2):246-55. PubMed ID: 25254416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation.
    Saint-Marcoux F; Debord J; Undre N; Rousseau A; Marquet P
    Ther Drug Monit; 2010 Apr; 32(2):129-35. PubMed ID: 20110850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients.
    Chen B; Shi HQ; Liu XX; Zhang WX; Lu JQ; Xu BM; Chen H
    J Clin Pharm Ther; 2017 Dec; 42(6):679-688. PubMed ID: 28833329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients.
    Glowacki F; Lionet A; Hammelin JP; Labalette M; Provôt F; Hazzan M; Broly F; Noël C; Cauffiez C
    Clin Pharmacokinet; 2011 Jul; 50(7):451-9. PubMed ID: 21528942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited sampling strategy for estimating individual exposure of tacrolimus in pediatric kidney transplant patients.
    Zhao W; Fakhoury M; Baudouin V; Maisin A; Deschênes G; Jacqz-Aigrain E
    Ther Drug Monit; 2011 Dec; 33(6):681-7. PubMed ID: 22011724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Bayesian Forecasting Methods for Prediction of Tacrolimus Exposure Using Samples Taken on Two Occasions in Adult Kidney Transplant Recipients.
    Brooks E; Tett SE; Isbel NM; McWhinney B; Staatz CE
    Ther Drug Monit; 2021 Apr; 43(2):238-246. PubMed ID: 32932413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.
    Jacobo-Cabral CO; García-Roca P; Romero-Tejeda EM; Reyes H; Medeiros M; Castañeda-Hernández G; Trocóniz IF
    Br J Clin Pharmacol; 2015 Oct; 80(4):630-41. PubMed ID: 25846845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating tacrolimus pharmacokinetic models in adult renal transplant recipients with different CYP3A5 genotypes.
    Hu C; Yin WJ; Li DY; Ding JJ; Zhou LY; Wang JL; Ma RR; Liu K; Zhou G; Zuo XC
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1437-1447. PubMed ID: 30019212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients.
    Kassir N; Labbé L; Delaloye JR; Mouksassi MS; Lapeyraque AL; Alvarez F; Lallier M; Beaunoyer M; Théorêt Y; Litalien C
    Br J Clin Pharmacol; 2014 Jun; 77(6):1051-63. PubMed ID: 24977292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.